Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat

Oprettet 03/07/2012 – 08:59

Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *